CDK4 and breast cancer: Our data are consistent with an onco-suppressor model in which OHPg/PR-B act as novel inhibitors of CD1/Cdk4, thus promoting the mesenchymal-epithelial transition and the reduction of breast cancer cell aggressiveness.